Chloroquine

Breastfeeding

See adverse reactions attributed to class:

Antimalarial

COVID-19 putative drug

Angioedema <1%

(1993): Lakartidningen (Swedish) 90, 54

Bullous pemphigoid 

(1999): Millard TP+, Clin Exp Dermatol 24, 263

Dermatitis 

(1984): Kellett JK+, Contact Dermatitis 11, 47

(1975): Skog E, Contact Dermatitis 1, 187

Desquamation 

(2002): Pages F+, Trop Med Int Health 7(11), 919 (with proguanil)

Ephelides 

(1985): Dupre A+, Arch Dermatol 121, 1164

Erythema annulare centrifugum 

(1982): Koralewski F, Dermatosen (German) 30, 125

(1967): Ashurst PJ, Arch Dermatol 95, 37

Erythema multiforme <1%

(package insert)

Erythroderma 

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1986): Langtry JA+, Br Med J Clin Res Ed 292, 1107

(1985): Slagel GA+, J Am Acad Dermatol 12, 857

Exanthems <5%

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

Exfoliative dermatitis 

(1986): Lavrijsen APM+, Acta Derm Venereol (Stockh) 66, 536

(1985): Slagel GA+, J Am Acad Dermatol 12, 857

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

Fixed eruption <1%

(package insert)

Lichenoid eruption 

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1981): Koranda FC, J Am Acad Dermatol 4, 650 [REVIEW] (passim)

(1979): Krebs A, Hautarzt (German) 30, 281

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

(1958): Savage J, Br J Dermatol 70, 181

(1948): Alving AS+, J Clin Invest 27, 56

Necrotizing vasculitis 

(2003): Luong MS+, Acta Derm Venereol 83(2), 141

Pemphigus 

(2006): Ghaffarpour G+, Int J Dermatol 45(10), 1261

Photosensitivity 

(2002): Pages F+, Trop Med Int Health 7(11), 919 (with proguanil)

(1993): Lakartidningen (Swedish) 90, 54

(1992): Seideman P+, Scand J Rheumatol 21(5), 245

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1989): Ortel B+, Dermatologica 178, 39

(1982): van Weelden H, Arch Dermatol 118, 290

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

(1968): Reed WB+, Arch Dermatol 98, 327

Phototoxicity 

(1998): Selvaag E, J R Army Med Corps 144(3), 163

Pigmentation 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2009): Gallo CB+, Clin Exp Dermatol 34(7), e266

(2008): Puri PK+, J Cutan Pathol 35(12), 1134 (passim)

(2006): Anders HJ+, Med Klin (Munich) 101(5), 421

(2006): Reynaert S+, J Eur Acad Dermatol Venereol 20(4), 487

(1998): Guedira N+, Rev Rhum Engl Ed 65, 58 [REVIEW]

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1987): Krebs A, Schweiz Rundsch Med Prax (German) 76, 1069

(1982): Levy H, S Afr Med J 62, 735

(1981): Koranda FC, J Am Acad Dermatol 4, 650 [REVIEW] (passim)

(1980): Bentsi-Enchill KO, Trop Geogr Med 32, 216

(1975): Marriott P+, Proc R Soc Med 68, 535

(1968): Stewart TW+, Acta Derm Venereol 48, 47

(1963): Tuffanelli D+, Arch Dermatol 88, 419

(1959): Dall JLC+, BMJ 1, 1387

Pruritus 

(2014): Sagara I+, Malar J 13(1), 458 (with azithromycin)

(2014): Ursing J+, PLoS One 9(1), e86801Pediatric

(2013): Ballut PC+, Acta Trop 128(3), 50420%

(2009): Gama H+, Gac Sanit 23(4), 30630%

(2009): Nakibuuka V+, Malar J 8, 237Pediatric

(2004): Ajayi AA+, Int J Dermatol 43(12), 972

(2000): Ademowo OG+, Clin Pharm Ther 67, 237

(1999): Millard TP+, Clin Exp Dermatol 24, 263

(1997): Adebayo RA+, Br J Clin Pharmacol 44, 157

(1997): Sowunmi A+, Trans R Trop Med Hyg 91, 63

(1996): George AO, Int J Dermatol 35, 323

(1995): Osifo NG, Afr J Med Sci 24, 67

(1992): Ogunranti JO+, Eur J Clin Pharmacol 43, 323

(1991): Ajayi AA+, Eur J Clin Pharmacol 41, 383

(1991): Ezeamuzie IC+, J Trop Med Hyg 94, 184

(1991): Mnyika KS, East Afr Med J 68, 139

(1991): Mnyika KS+, J Trop Med Hyg 94, 2747%

(1991): Okor RS, J Clin Pharm Ther 16, 463

(1990): Abdulkadir SA+, Trans Roy Soc Trop Med Hyg 84, 898

(1990): Okor RS, J Clin Pharm Ther 15, 147

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1989): Abila B+, J Trop Med Hyg 92, 356

(1989): Burnham G+, Trans R Soc Trop Med Hyg 83, 527

(1989): Hallwood PM+, Lancet 2, 397

(1989): Osifo NG, Afr J Med Sci 18, 121

(1989): Soro B+, Bull Soc Pathol Exot Filiales (French) 82, 88

(1989): Sowunmi A+, Lancet 2, 213

(1987): Spencer HC+, Ann Trop Med Parasitol 81, 124

(1986): Harries AD+, Ann Trop Med Parasitol 80, 479

(1984): Bhasin V+, J Indian Med Assoc 82, 447

(1984): Caussade P, Arch Fr Pediatr (French) 41, 727

(1984): Osifo NG, Arch Dermatol 120, 80

(1982): Spencer HC+, BMJ 285, 1703

(1977): Olatunde A, Afr J Med Sci 6, 27

(1969): Olatunde IA, J Nigerian Med Assoc 6, 23

(1964): Ekpechi OL+, Arch Dermatol 89, 631

Psoriasis 

(2017): Balak DM+, Psoriasis (Auckl) 7, 87 [REVIEW]

(1998): Wilairatana P+, Int J Dermatol 37, 713

(1997): Wilairatana P+, Int J Dermatol 36, 634

(1993): Schopf RE+, Dermatology 187(2), 100

(1992): Vestey JP+, J Infect 24, 211

(1991): Damstra RJ+, Ned Tijdschr Geneeskd (Dutch) 135, 671

(1990): Abdulkadir SA+, Trans R Soc Trop Med Hyg 84, 898

(1990): Katugampola G+, Int J Dermatol 29, 153

(1990): Okor RS, J Clin Pharm Ther 15, 147

(1989): Mallett R+, BMJ 299, 1400

(1988): Nicolas J-F+, Ann Dermatol Venereol (French) 115, 289

(1987): Friedman SJ, J Am Acad Dermatol 16, 1256

(1985): Stone OJ, Int J Dermatol 24, 539

(1982): Abel EA+, J Am Acad Dermatol 15, 2007

(1982): Luzar MJ, J Rheumatol 9, 462

(1981): Olsen TG, Ann Intern Med 94, 546

(1980): Kuflik EG, Cutis 26, 153

(1966): Baker H, Br J Dermatol 78, 161

(1957): Cornbleet T+, Arch Dermatol 75, 286

Pustules 

(1990): Lotem M+, Acta Derm Venereol (Stockh) 70, 250

Rash 

(2009): Nakibuuka V+, Malar J 8, 237Pediatric

Stevens-Johnson syndrome 

(2000): Madnani N, Mumbai, India (personal communication / observation)

(1989): Ortel B+, Dermatologica 178, 39

(1987): Lenox-Smith I, J Infect 14(1), 90 (fatal)Fatal (with sulfadoxine and pyrimethamine)

(1986): Bamber MG+, J Infect 13(1), 31 (fatal)FatalPediatric (with pyrimethamine and sulfadoxine (Fansidar))

Toxic epidermal necrolysis <1%

(1994): Boffa MJ+, Br J Dermatol 131, 444

(1988): Phillips-Howard PA+, Br Med J Clin Res Ed 296, 1605

(1979): Bazarnaia NS+, Ter Arkh (Russian) 51, 99

(1976): Kanwar AJ+, Indian J Dermatol 21, 73

(1972): Sov Med (Russian) 35, 133

Toxicity 

(2015): Al-Bari MA, J Antimicrob Chemother 70(6), 1608

(2008): Cooper RG+, Indian J Med Res 127 (4), 305 [REVIEW]

Urticaria 

(2019): Balamurugesan K+, J Family Med Prim Care 8(7), 2545 (1 case)

(2002): Pages F+, Trop Med Int Health 7(11), 919 (with proguanil)

(1990): Simoneaux PW, Curr Concept Skin Dis Winter, 15

(1981): Koranda FC, J Am Acad Dermatol 4(6), 650 [REVIEW] (passim)

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

Vitiligo 

(2003): Martin-Garcia RF+, J Am Acad Dermatol 48(6), 981

(1998): Selvaag E, J R Army Med Corps 144(3), 163

(1997): Selvaag E, Ann Trop Pediatr 17, 45

(1996): Selvaag E, Acta Derm Venereol 76, 166 [REVIEW]

(1996): Selvaag E, Trans R Trop Med Hyg 90, 683

(1992): Gonggryp LA+, Br J Rheumatol 31, 790

(1980): Bentsi-Enchill KO, Trop Geogr Med 32, 216

Hair pigmentation <1%

(2010): Donovan JC+, N Engl J Med 363(4), 372

(2009): Di Giacomo TB+, Lupus 18(3), 264

(1997): Asch PH+, Ann Dermatol Venereol (French) 124, 552

(1992): Bublin JG+, J Clin Pharm Ther 17, 297 [REVIEW]

(1991): Ochsendorf FR+, Hautarzt (German) 42, 140

(1981): Koranda FC, J Am Acad Dermatol 4, 650 [REVIEW] (passim)

(1978): Dubois EL, Semin Arthritis Rheum 8, 33 [REVIEW]

(1976): Sams WM, Int J Dermatol 15, 99 [REVIEW]

(1973): Rees RB+, Arch Dermatol 88, 280 (passim)

(1965): Rook A, Br J Dermatol 77, 115

Poliosis 

(1985): Dupre A+, Arch Dermatol 121, 1164

(1968): Pasykowa K+, Pol Tyg Lek (Polish) 23, 2014

(1966): Fraga S+, An Bras Dermatol (Portuguese) 41, 57

Discoloration 

(1991): Zic JA+, Arch Dermatol 127, 1037

Nail pigmentation 

(1981): Koranda FC, J Am Acad Dermatol 4, 650 [REVIEW] (passim)

(1963): Tuffanelli D+, Arch Dermatol 88, 419

Shoreline nails 

(1993): Pavithran K, Indian J Lepr 65, 225

Mucosal membrane pigmentation 

(2011): Moraes PC+, Minerva Stomatol 60(6), 327 (in the lower lip)

(2005): Fardet L+, Ann Dermatol Venereol 132(8-9 Pt 1), 665 [REVIEW]

Oral pigmentation 

(2017): de Andrade BA+, J Clin Exp Dent 9(12), e1487

(2013): de Andrade BA+, J Cutan Pathol 40(9), 833 (5 cases)

(2012): Brasil Cda M+, Gen Dent 60(2), e74 (hard palate)

(2012): de Melo Filho MR+, Head Neck Pathol 6(1), 48

(2011): Moraes PC+, Minerva Stomatol 60(6), 327

(2009): Gallo CB+, Clin Exp Dermatol 34(7), e266

(1992): Veraldi S+, Cutis 49, 281

(1991): Zic JA+, Arch Dermatol 127, 1037

(1990): Wollina U+, Dtsch Z Mund Kiefer Gesichtschir (German) 14, 104

(1981): Koranda FC, J Am Acad Dermatol 4, 650 [REVIEW] (passim)

(1980): Bentsi-Enchill KO, Trop Geogr Med 32, 216

(1971): Giansanti JS+, Oral Surg 31, 66

(1970): Brynolf I, Sven Tandlak Tidskr (Swedish) 63, 585

Oral ulceration 

(2002): Pages F+, Trop Med Int Health 7(11), 919 (with proguanil)

Stomatitis <1%

(package insert)

Atrioventricular block 

(2014): Lopez-Ruiz N+, BMJ Case Rep Sep, Epub

(2008): Puymirat E+, Rev Med Interne (French) 29(9), 741

Cardiac arrest 

(2009): Aslanger E+, Resuscitation 80(2), 285

Cardiac failure 

(2018): Yogasundaram H+, ESC Heart Fail Feb, Epub ahead of print (reversible)

(2009): Fragasso G+, Heart Vessels 24(5), 385

(1999): Baguet JP+, Heart 81(2), 221 [REVIEW]

Cardiomyopathy 

(2018): Yogasundaram H+, ESC Heart Fail Feb, Epub ahead of print

(2014): Lopez-Ruiz N+, BMJ Case Rep Sep, Epub

(2012): Azimian M+, J Clin Rheumatol 18(7), 363 (fatal / 2 cases)Fatal

(2012): Tonnesmann E+, J Rheumatol 39(5), 1099

(2007): Hernandez Jimenez V+, Med Clin (Barc) (Spanish) 129(4), 157

(2005): Naqvi TZ+, J Am Soc Echocardiogr 18(4), 383

(1999): Baguet JP+, Heart 81(2), 221 [REVIEW]

(1993): Iglesias Cubero G+, Br Heart J 69(5), 451

(1987): McAllister HA Jr+, Arch Pathol Lab Med 111(10), 953

Cardiotoxicity 

(2011): Gentille Lorente DI, Rev Med Chil (Spanish) 139(10), 1384

(2009): Fragasso G+, Heart Vessels 24(5), 385

(2009): Saussine A+, Ann Dermatol Venereol (French) 136(6-7), 530

Congestive heart failure 

(2005): Naqvi TZ+, J Am Soc Echocardiogr 18(4), 383

(1993): Iglesias Cubero G+, Br Heart J 69(5), 451

Myocardial toxicity 

(2006): Mata Martin AM+, Rev Clin Esp 206(2), 111

(2001): Cervera A+, Ann Rheum Dis 60(3), 301

QT prolongation 

(2015): Isbister GK, Aust Prescr 38(1), 20

(2008): Stas P+, Int J Cardiol 127 (2), e80

(2004): Abriel H+, Swiss Med Wkly 134(47-48), 685 [REVIEW]

Tachycardia 

(1993): Fauchier JP+, Arch Mal Coeur Vaiss 86(5 Suppl), 757 [REVIEW]

Torsades de pointes 

(2015): Isbister GK, Aust Prescr 38(1), 20

(2006): Chen CY+, Clin Toxicol (Phila) 44(2), 173

Ventricular arrhythmia 

(2020): Mehra MR+, Lancet May, Online ahead of print4%

Ventricular tachycardia 

(2008): Stas P+, Int J Cardiol 127 (2), e80

Amnesia 

(1990): Cras P+, J Neurol Neurosurg Psychiatry 53(10), 926

Anorexia 

(2011): Poravuth Y+, PLoS One 6(1), e145014%

Headache 

(2014): Sagara I+, Malar J 13(1), 458 (with azithromycin)

(2011): Paton NI+, Lancet Infect Dis 11(9), 677

(2011): Poravuth Y+, PLoS One 6(1), e1450115%

(2002): Albright TA+, J Travel Med 9(6), 289

Paranoia 

(2016): Bogaczewicz A+, Int J Dermatol 55(12), 1378

Psychosis 

(2014): Biswas PS+, Gen Hosp Psychiatry 36(2), 181

(2010): Jousset N+, Am J Forensic Med Pathol 31(4), 378 (with mefloquine / suicide)

(2007): Sahoo S+, Am J Ther 14(4), 406

(1992): Gupte S, Ann Trop Paediatr 12(2), 229

Seizures 

(2004): Tristano AG+, Rheumatol Int 24(5), 315

(2003): Reuther LO+, Ugeskr Laeger 165(14), 1447 [REVIEW]

Vertigo (dizziness) 

(2014): Sagara I+, Malar J 13(1), 458 (with azithromycin)

(2011): Paton NI+, Lancet Infect Dis 11(9), 677

(2011): Poravuth Y+, PLoS One 6(1), e145013%

(2007): Bortoli R+, Clin Rheumatol 26 (11), 1809

Porphyria 

(1980): Gerwel M, Pol Tyg Lek (Polish) 35, 1351

(1974): Kordac V+, Br J Dermatol 90, 95

(1973): Knutsson F+, Lakartidningen (Swedish) 70, 1547

(1962): Cripps DL+, Arch Dermatol 86, 575

(1959): Marsden CW, Br J Dermatol 71, 219

(1957): Davis MJ+, Arch Dermatol 75, 796

(1954): Linden IH+, Calif Med 81, 235

Porphyria cutanea tarda 

(1985): Handa F+, Indian J Dermatol 30, 49

Diarrhea 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2011): Paton NI+, Lancet Infect Dis 11(9), 677

Dysphagia 

(2007): Mateen FJ+, Can J Neurol Sci 34(3), 377

Gastrointestinal ulceration 

(2010): Roux X+, Med Trop (Mars) (French) 70(5-6), 423 (with proguanil)

Hepatitis 

(2011): Paton NI+, Lancet Infect Dis 11(9), 677 (serious / 1 case)

Nausea 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2011): Paton NI+, Lancet Infect Dis 11(9), 677

(2002): Albright TA+, J Travel Med 9(6), 289

Vomiting  

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2014): Sagara I+, Malar J 13(1), 458 (with azithromycin)

(2011): Poravuth Y+, PLoS One 6(1), e145013%

(2010): Tricou V+, PLoS Negl Trop Dis 4(8), e785

(2009): Nakibuuka V+, Malar J 8, 237Pediatric

Asthenia (fatigue) 

(2011): Poravuth Y+, PLoS One 6(1), e145015%

Ataxia 

(2008): Milic V+, Rheumatol Int 28(12), 1295

Myalgia/Myositis/Myopathy/Myotoxicity 

(2011): Poravuth Y+, PLoS One 6(1), e145019%

(2011): Posada C+, Lupus 20(7), 773

(2007): Mateen FJ+, Can J Neurol Sci 34(3), 377

(2005): Haberl A+, Z Rheumatol 64(4), 274

(1998): Guedira N+, Rev Rhum Engl Ed 65, 58 [REVIEW]

(1971): Br Med J 2(5762), 605

(1971): Hughes JT+, Q J Med 40(157), 85

(1969): Chapman RS+, Br J Dermatol 81(anal), 217

Myasthenia gravis 

(2008): Ritenour RJ+, Can J Ophthalmol 43(2), 241

(1999): Klimek A, Neurol Neurochir Pol 33(4), 951

(1996): Bruggemann W+, Med Klin (Munich) 91(5), 268 (1 case)

(1991): De Bleecker J+, Acta Clin Belg 46(6), 401

(1989): Robberecht W+, Arch Neurol 46(4), 464 [REVIEW]

(1988): Sghirlanzoni A+, Muscle Nerve 11(2), 114

(1981): Schumm F+, Dtsch Med Wochenschr, 1745

Corneal deposits 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]<90%

(2007): Leecharoen S+, J Med Assoc Thai 90(1), 52

Diplopia (double vision) 

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

Keratopathy 

(2012): Ma X+, Curr Eye Res 37(4), 293

(2005): Inada ET+, Arq Bras Oftalmol 68(3), 407

Maculopathy 

(2014): Bursztyn LL+, Retin Cases Brief Rep 8(4), 322

(2005): Inada ET+, Arq Bras Oftalmol 68(3), 407

(1985): Taylor F, Aust Fam Physician 14(8), 744

Ocular adverse effect 

(2010): Lacava AC, Arq Bras Oftalmol (Portuguese) 73(4), 384

(2007): Leecharoen S+, J Med Assoc Thai 90(1), 5235%

Ocular toxicity 

(2011): Gentille Lorente DI, Rev Med Chil (Spanish) 139(10), 1384

(2007): Bortoli R+, Clin Rheumatol 26 (11), 1809

(2005): Inada ET+, Arq Bras Oftalmol 68(3), 407

(2002): Grana Gil+, An Med Interna 19(4), 189

Retinopathy 

(2016): Bourgeois N+, Therapie (French) 71(4), 365

(2015): Costedoat-Chalumeau N+, Clin Rev Allergy Immunol 49 3), 317 [REVIEW]

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 39641%

(2014): Rodriguez-Caruncho C+, Actas Dermosifiliogr 105(3), 243 [REVIEW]

(2007): Ferreras A+, Arch Soc Esp Oftalmol 82(2), 103

(2007): Leecharoen S+, J Med Assoc Thai 90(1), 52

(2006): Ingster-Moati I+, J Fr Ophtalmol (French) 29(6), 642

(2006): Kellner U+, Invest Ophthalmol Vis Sci 47(8), 3531

(2005): Fardet L+, Ann Dermatol Venereol 132(8-9 Pt 1), 665 [REVIEW]

(2004): Araiza-Casillas R+, Lupus 13(2), 119

Vision blurred 

(2011): Paton NI+, Lancet Infect Dis 11(9), 677

(2009): Nakibuuka V+, Malar J 8, 237Pediatric

Vision impaired 

(2005): Tzekov R, Doc Ophthalmol 110(1), 111 [REVIEW]

Hearing loss 

(2007): Bortoli R+, Clin Rheumatol 26(11), 1809 [REVIEW]

Ototoxicity 

(2007): Bortoli R+, Clin Rheumatol 26(11), 1809 [REVIEW]

Tinnitus 

(2007): Bortoli R+, Clin Rheumatol 26(11), 1809 [REVIEW]

Renal phospholipidosis 

(2003): Muller-Hocker J+, Hum Pathol 34(3), 285 (1 case)

Cough 

(2011): Poravuth Y+, PLoS One 6(1), e145012%

Flu-like syndrome 

(2007): Rossmann-Ringdahl I+, Acta Derm Venereol 87(5), 401

Nasopharyngitis 

(2011): Poravuth Y+, PLoS One 6(1), e145013%

Adverse effects 

(2020): Patil VM+, Life Sci May, Online ahead of print [REVIEW]

(2014): Chopra A+, Arthritis Rheumatol 66(2), 319 (mild)

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 396

Death 

(2012): Azimian M+, J Clin Rheumatol 18(7), 363 (2 cases)

(1987): Lenox-Smith I, J Infect 14(1), 90

(1986): Bamber MG+, J Infect 13(1), 31Pediatric (with pyrimethamine and sulfadoxine (Fansidar))

Side effects 

(2008): Cooper RG+, Indian J Med Res 127(4), 305 [REVIEW]



Adverse reactions attributed to entire drug class Antimalarial

Hypersensitivity 

(2011): Singalavanija S+, J Med Assoc Thai 94 Suppl 3, S852%

Pigmentation 

(2016): Krause W, G Ital Dermatol Venereol 151(6), 694 [REVIEW]

(2013): Janier M, Ann Dermatol Venereol (French) 140 Suppl 3, s237

(2013): Krause W, J Dtsch Dermatol Ges 11(7), 644 [REVIEW]

QT prolongation 

(2010): Bril F+, Curr Drug Saf 5 (1), 85

Ocular toxicity 

(2014): Schneider C+, Travel Med Infect Dis 12(1), 40

(2013): Audo I, Rev Prat (French) 63(1), 63 [REVIEW]

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect 

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Page last updated 05/26/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top